

09/831,629

- 1 -

FILE 'CA' ENTERED AT 16:35:07 ON 23 MAY 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.06	295.14

=> s KAYE/SQEP OR KYAE/SQEP OR AYEG/SQEP OR GEYA/SQEP

*** REGISTRY INITIATED ***

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L16 5 L15

*** REGISTRY INITIATED ***

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L18 4 L17

*** REGISTRY INITIATED ***

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L20 1 L19

*** REGISTRY INITIATED ***

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L22 0 L21

L23 6 L22 OR L20 OR L18 OR L16

=> FILE REG

=> S KAYE/SQEP OR KYAE/SQEP OR AYES/SQEP OR GEYA/SQEP

0 KAYE/SQEP
66370 SQL=4
0 KAYE/SQEP
(KAYE/SQEP AND SQL=4)
1 KYAE/SQEP
66370 SQL=4
1 KYAE/SQEP
(KYAE/SQEP AND SQL=4)
8 AYES/SQEP
66370 SQL=4
8 AYES/SQEP
(AYES/SQEP AND SQL=4)
2 GEYA/SQEP
66370 SQL=4
2 GEYA/SQEP
(GEYA/SQEP AND SQL=4)

L24 11 KAYE/SQEP OR KYAE/SQEP OR AYES/SQEP OR GEYA/SQEP

=> S AYES/SQEP OR GAYE/SQEP OR GEYA/SQEP OR AYES/SQEP

8 AYES/SQEP
66370 SQL=4
8 AYES/SQEP
(AYES/SQEP AND SQL=4)
2 GAYE/SQEP
66370 SQL=4
2 GAYE/SQEP
(GAYE/SQEP AND SQL=4)
2 GEYA/SQEP
66370 SQL=4
2 GEYA/SQEP
(GEYA/SQEP AND SQL=4)
8 AYES/SQEP
66370 SQL=4
8 AYES/SQEP
(AYES/SQEP AND SQL=4)

L25 10 AYES/SQEP OR GAYE/SQEP OR GEYA/SQEP OR AYES/SQEP

=> S GEYA/SQEP OR EYAG/SQEP

2 GEYA/SQEP
66370 SQL=4
2 GEYA/SQEP
(GEYA/SQEP AND SQL=4)
12 EYAG/SQEP
66370 SQL=4
12 EYAG/SQEP
(EYAG/SQEP AND SQL=4)

L26 12 GEYA/SQEP OR EYAG/SQEP

=> D HISTORY

(FILE 'HOME' ENTERED AT 16:21:30 ON 23 MAY 2005)

FILE 'REGISTRY' ENTERED AT 16:21:34 ON 23 MAY 2005
L1 1 S KEAK/SQEP OR KDAK/SQEP OR KEGK/SQEP OR KDGK/SQEP
L2 1 S KEAR/SQEP OR KDAR/SQEP OR KEGR/SQEP OR KDGR/SQEP
L3 1 S KAER/SQEP OR KADR/SQEP OR KAER/SQEP OR KGDR/SQEP
L4 0 S KAEK/SQEP OR KADK/SQEP OR KAEK/SQEP OR KGDK/SQEP
L5 0 S REAK/SQEP OR RDAK/SQEP OR REGK/SQEP OR RDGK/SQEP
L6 3 S RAEK/SQEP OR RADK/SQEP OR RAEK/SQEP OR RGDK/SQEP
L7 0 S EKAK/SQEP OR DKAK/SQEP OR EKGK/SQEP OR DKGK/SQEP
L8 1 S EKAR/SQEP OR DKAR/SQEP OR EKGR/SQEP OR DKGR/SQEP
L9 0 S AKER/SQEP OR AKDR/SQEP OR GKER/SQEP OR AKDR/SQEP
L10 2 S AKEK/SQEP OR AKDK/SQEP OR GKEK/SQEP OR AKDK/SQEP
L11 9 S L1-L10

FILE 'CA' ENTERED AT 16:26:53 ON 23 MAY 2005
L12 17 S L11
L13 10574 S HOST ADJ2 GRAFT OR ORGAN ALLOGRAFT OR TRANSPLANT REJECTION OR
L14 0 S L12 AND L13
S KAYE/SQEP OR KYAE/SQEP OR AYEG/SQEP OR GEYA/SQEP

FILE 'REGISTRY' ENTERED AT 16:35:18 ON 23 MAY 2005
L15 2 S GEYA/SQEP

FILE 'CA' ENTERED AT 16:35:21 ON 23 MAY 2005
L16 5 S L15

FILE 'REGISTRY' ENTERED AT 16:35:21 ON 23 MAY 2005
L17 8 S AYEG/SQEP

FILE 'CA' ENTERED AT 16:35:24 ON 23 MAY 2005
L18 4 S L17

FILE 'REGISTRY' ENTERED AT 16:35:24 ON 23 MAY 2005
L19 1 S KYAE/SQEP

FILE 'CA' ENTERED AT 16:35:27 ON 23 MAY 2005
L20 1 S L19

FILE 'REGISTRY' ENTERED AT 16:35:27 ON 23 MAY 2005
L21 0 S KAYE/SQEP

FILE 'CA' ENTERED AT 16:35:31 ON 23 MAY 2005
L22 0 S L21
L23 6 S L22 OR L20 OR L18 OR L16

FILE 'REGISTRY' ENTERED AT 16:35:34 ON 23 MAY 2005
L24 11 S KAYE/SQEP OR KYAE/SQEP OR AYEG/SQEP OR GEYA/SQEP
L25 10 S AYEG/SQEP OR GAYE/SQEP OR GEYA/SQEP OR AYEG/SQEP
L26 12 S GEYA/SQEP OR EYAG/SQEP

=> s 124-126
L27 21 (L24 OR L25 OR L26)

=> file ca

=> s 127

L28 6 L27

=> d history

(FILE 'HOME' ENTERED AT 16:21:30 ON 23 MAY 2005)

FILE 'REGISTRY' ENTERED AT 16:21:34 ON 23 MAY 2005

L1 1 S KEAK/SQEP OR KDAK/SQEP OR KEGK/SQEP OR KDGK/SQEP
L2 1 S KEAR/SQEP OR KDAR/SQEP OR KEGR/SQEP OR KDGR/SQEP
L3 1 S KAER/SQEP OR KADR/SQEP OR KAER/SQEP OR KGDR/SQEP
L4 0 S KAEK/SQEP OR KADK/SQEP OR KAEK/SQEP OR KGDK/SQEP
L5 0 S REAK/SQEP OR RDAK/SQEP OR REGK/SQEP OR RDGK/SQEP
L6 3 S RAEK/SQEP OR RADK/SQEP OR RAEK/SQEP OR RGDK/SQEP
L7 0 S EKAK/SQEP OR DKAK/SQEP OR EKGK/SQEP OR DKGK/SQEP
L8 1 S EKAR/SQEP OR DKAR/SQEP OR EKGR/SQEP OR DKGR/SQEP
L9 0 S AKER/SQEP OR AKDR/SQEP OR GKER/SQEP OR AKDR/SQEP
L10 2 S AKEK/SQEP OR AKDK/SQEP OR GKEK/SQEP OR AKDK/SQEP
L11 9 S L1-L10

FILE 'CA' ENTERED AT 16:26:53 ON 23 MAY 2005

L12 17 S L11
L13 10574 S HOST ADJ2 GRAFT OR ORGAN ALLOGRAFT OR TRANSPLANT REJECTION OR
L14 0 S L12 AND L13
S KAYE/SQEP OR KYAE/SQEP OR AYEG/SQEP OR GEYA/SQEP

FILE 'REGISTRY' ENTERED AT 16:35:18 ON 23 MAY 2005

L15 2 S GEYA/SQEP

FILE 'CA' ENTERED AT 16:35:21 ON 23 MAY 2005

L16 5 S L15

FILE 'REGISTRY' ENTERED AT 16:35:21 ON 23 MAY 2005

L17 8 S AYEG/SQEP

FILE 'CA' ENTERED AT 16:35:24 ON 23 MAY 2005

L18 4 S L17

FILE 'REGISTRY' ENTERED AT 16:35:24 ON 23 MAY 2005

L19 1 S KYAE/SQEP

FILE 'CA' ENTERED AT 16:35:27 ON 23 MAY 2005

L20 1 S L19

FILE 'REGISTRY' ENTERED AT 16:35:27 ON 23 MAY 2005

L21 0 S KAYE/SQEP

FILE 'CA' ENTERED AT 16:35:31 ON 23 MAY 2005

L22 0 S L21

L23 6 S L22 OR L20 OR L18 OR L16

FILE 'REGISTRY' ENTERED AT 16:35:34 ON 23 MAY 2005

L24 11 S KAYE/SQEP OR KYAE/SQEP OR AYEG/SQEP OR GEYA/SQEP
L25 10 S AYEG/SQEP OR GAYE/SQEP OR GEYA/SQEP OR AYEG/SQEP
L26 12 S GEYA/SQEP OR EYAG/SQEP
L27 21 S L24-L26

FILE 'CA' ENTERED AT 16:36:39 ON 23 MAY 2005
L28 6 S L27

=> s l13 and l28
L29 0 L13 AND L28

=> s immunosuppres?
L30 44974 IMMUNOSUPPRES?

=> s l22 or l28
L31 6 L22 OR L28

=> s l11 or l28
17 L11
L32 23 L11 OR L28

=> s l32 and l30
L33 3 L32 AND L30

=> d bib ab 1-3

L33 ANSWER 1 OF 3 CA COPYRIGHT 2005 ACS on STN
AN 140:58438 CA
TI Monoclonal anti-MUC1 antibody PAM4 and chimeric antibodies for diagnosis
and therapy of pancreatic cancer
IN Gold, David V.; Goldenberg, David M.; Hansen, Hans
PA Immunomedics, Inc., USA; McCall, John Douglas
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003106497	A1	20031224	WO 2003-GB2585	20030616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489469	AA	20031224	CA 2003-2489469	20030616
US 2004057902	A1	20040325	US 2003-461878	20030616
EP 1521775	A1	20050413	EP 2003-760086	20030616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-388313P	P	20020614		
WO 2003-GB2585	W	20030616		

AB This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a

target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-assocd. antibody designated PAM4. The invention further relates to chimeric PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 2 OF 3 CA COPYRIGHT 2005 ACS on STN

AN 140:58437 CA

TI Multivalent humanized monoclonal anti-MUC1 antibody PAM4 for diagnosis and treatment of cancer

IN Goldenberg, David M.; Hansen, Hans; Qu, Zhengxing

PA Immunomedics, Inc., USA; McCall, John Douglas

SO PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003106495	A2	20031224	WO 2003-GB2593	20030616
	WO 2003106495	A3	20040401		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2489467	AA	20031224	CA 2003-2489467	20030616
	US 2005014207	A1	20050120	US 2003-461885	20030616
	EP 1519958	A2	20050406	EP 2003-740743	20030616
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	US 2002-388314P	P	20020614		
	WO 2003-GB2593	W	20030616		

AB This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-assocd. antibody designated PAM4. The invention further relates to humanized and human PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.

L33 ANSWER 3 OF 3 CA COPYRIGHT 2005 ACS on STN
 AN 132:132335 CA
 TI Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
 IN Aharoni, Rina; Teitelbaum, Dvora; Arnon, Ruth; Sela, Michael; Fridkis-Hareli, Masha; Strominger, Jack L.
 PA Yeda Research and Development Co., Ltd, Israel; President and Fellows of Harvard College
 SO PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005250	A1	20000203	WO 1999-US16747	19990723
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, US, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2337688	AA	20000203	CA 1999-2337688	19990723
	AU 9952262	A1	20000214	AU 1999-52262	19990723
	AU 768782	B2	20040108		
	EP 1098902	A1	20010516	EP 1999-937423	19990723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002521387	T2	20020716	JP 2000-561206	19990723
	NZ 509901	A	20031031	NZ 1999-509901	19990723
	US 6514938	B1	20030204	US 1999-405743	19990924
	ZA 2001000366	A	20020114	ZA 2001-366	20010112
	NO 2001000329	A	20010308	NO 2001-329	20010119
	US 2002055466	A1	20020509	US 2001-768872	20010123
	US 2004006022	A1	20040108	US 2003-438538	20030515
PRAI	US 1998-93859P	P	19980723		
	US 1998-101825P	P	19980925		
	US 1998-102960P	P	19981002		
	US 1998-106350P	P	19981030		
	US 1998-108184P	P	19981112		
	US 1999-123675P	P	19990309		
	US 1998-101693P	P	19980925		
	US 1999-359099	A3	19990722		
	WO 1999-US16747	W	19990723		

AB Polypeptides and peptides are disclosed which contain at least three amino acids randomly joined in a linear array, in which at least one of the three amino acids is an arom. amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliph. amino acid. In a preferred embodiment, the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the invention, the polypeptides bind to antigen-presenting cells, purified human lymphocyte antigens (HLA), and/or Copolymer 1-specific T cells. Moreover, these polypeptides can be

formulated into pharmaceutical compns. for treating autoimmune disease.
Also disclosed are methods of treating an autoimmune disease in a mammal
by administering a pharmaceutically effective amt. of any one of the
polypeptides or peptides.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.05	406.39

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.04	-2.04

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 16:39:08 ON 23 MAY 2005